文献速递脑血管病

专用脑静脉血栓清除装置的有效性与安全性:一项先导性随机临床试验

Efficacy and Safety of a Dedicated Device for Cerebral Venous Thrombectomy: A Pilot Randomized Clinical Trial.
PubMed 文献 · Stroke · 2024-11-27

这项先导性、前瞻性、随机、单盲、平行对照、单中心临床研究纳入北京宣武医院的61例脑静脉血栓形成患者,随机分配至Venous-TD组(31例)或Angioguard联合Sterling球囊对照组(30例)。Venous-TD显著提高术中完全再通比例(76.7% vs 20.0%,RR 3.833,95%CI 1.825-8.054),180天严重残余头痛比例显著降低(9.7% vs 35.7%,RR 0.271,95%CI 0.083-0.886),安全性结局两组无统计学显著差异。

要点

  • Venous-TD组术中完全再通比例76.7%,对照组20.0%,RR 3.833(95%CI 1.825-8.054)。
  • 180天严重残余头痛比例Venous-TD组9.7%,对照组35.7%,RR 0.271(95%CI 0.083-0.886)。
  • 安全性结局两组无统计学显著差异,需多中心III期随机对照试验进一步评估。

主要发现

  • Venous-TD组术中完全再通比例23例(76.7%),对照组6例(20.0%),相对危险度3.833(95%CI 1.825-8.054)。
  • Venous-TD组180天功能独立比例与对照组无显著差异。
  • Venous-TD组180天严重残余头痛比例3例(9.7%),对照组10例(35.7%),相对危险度0.271(95%CI 0.083-0.886)。
  • 安全性结局(围手术期并发症、全因死亡、症状性颅内出血)两组无统计学显著差异。

局限性

  • 原文指出需开展多中心III期随机对照试验评估Venous-TD的有效性与安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lack of a dedicated thrombectomy device for cerebral venous thrombosis hinders the recanalization ability of endovascular treatment (EVT). Novel NiTi-braided stent retriever (Venous-TD) is a dedicated venous sinus thrombectomy device. This study aims to demonstrate the safety and efficacy of Venous-TD. METHODS: In this pilot, prospective, randomized, single-blind, parallel-group control, single-center clinical study, patients with cerebral venous thrombosis from Beijing Xuanwu Hospital were included. Randomization was performed to EVT with either the Venous-TD or Angioguard with Sterling balloon (control group). The primary efficacy outcome was the proportion of immediate complete recanalization during EVT. Secondary outcomes included the proportion of functional independence and moderate to severe residential headache at 180 days after EVT. Safety outcomes included peri-procedural complications, all-cause mortality, and symptomatic intracranial hemorrhage after EVT. RESULTS: A total of 61 patients were enrolled and randomized. Thirty-one patients were randomized to the Venous-TD group, and 30 were randomized to the control group. The median (interquartile range) age was 28 (21-45) in the Venous-TD group and 34 (24-43) in the control group. The proportion of patients with a National Institutes of Health Stroke Scale score >8 on admission was 8 (25.8%) in the Venous-TD group and 11 (36.7%) in the control group. During EVT, Venous-TD significantly improved the proportion of complete recanalization compared with Angioguard (23 [76.7%] versus 6 [20.0%]; relative risk, 3.833 [95% CI, 1.825-8.054]). The proportions of long-term functional independence at 180 days in the Venous-TD group and the control group were not significantly different. The proportion of patients with severe residual headache at 180 days in the Venous-TD group was significantly lower than that in the control group (3 [9.7%] versus 10 [35.7%]; relative risk, 0.271 [95% CI, 0.083-0.886]). Safety outcomes showed no statistically significant difference between the 2 groups. CONCLUSIONS: This trial indicated that Venous-TD did not increase complications in EVT of cerebral venous thrombosis and can significantly increase the proportion of complete recanalization. A multicenter phase III randomized control trial assessing efficacy and safety of Venous-TD is warranted. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT05291585.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Xu Y, Wu Y, Jiang M, et al. Efficacy and Safety of a Dedicated Device for Cerebral Venous Thrombectomy: A Pilot Randomized Clinical Trial. Stroke. 2024. PMID: 39601121. doi:10.1161/STROKEAHA.124.045607

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。